213 related articles for article (PubMed ID: 21274871)
1. Acetylcholinesterase, a key prognostic predictor for hepatocellular carcinoma, suppresses cell growth and induces chemosensitization.
Zhao Y; Wang X; Wang T; Hu X; Hui X; Yan M; Gao Q; Chen T; Li J; Yao M; Wan D; Gu J; Fan J; He X
Hepatology; 2011 Feb; 53(2):493-503. PubMed ID: 21274871
[TBL] [Abstract][Full Text] [Related]
2. Myeloid differentiation factor 88 promotes growth and metastasis of human hepatocellular carcinoma.
Liang B; Chen R; Wang T; Cao L; Liu Y; Yin F; Zhu M; Fan X; Liang Y; Zhang L; Guo Y; Zhao J
Clin Cancer Res; 2013 Jun; 19(11):2905-16. PubMed ID: 23549880
[TBL] [Abstract][Full Text] [Related]
3. Leptin induces proliferation and anti-apoptosis in human hepatocarcinoma cells by up-regulating cyclin D1 and down-regulating Bax via a Janus kinase 2-linked pathway.
Chen C; Chang YC; Liu CL; Liu TP; Chang KJ; Guo IC
Endocr Relat Cancer; 2007 Jun; 14(2):513-29. PubMed ID: 17639064
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of CXCL5 mediates neutrophil infiltration and indicates poor prognosis for hepatocellular carcinoma.
Zhou SL; Dai Z; Zhou ZJ; Wang XY; Yang GH; Wang Z; Huang XW; Fan J; Zhou J
Hepatology; 2012 Dec; 56(6):2242-54. PubMed ID: 22711685
[TBL] [Abstract][Full Text] [Related]
5. The activation of MEK/ERK signaling pathway by bone morphogenetic protein 4 to increase hepatocellular carcinoma cell proliferation and migration.
Chiu CY; Kuo KK; Kuo TL; Lee KT; Cheng KH
Mol Cancer Res; 2012 Mar; 10(3):415-27. PubMed ID: 22241220
[TBL] [Abstract][Full Text] [Related]
6. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
7. Suppression by heat shock protein 20 of hepatocellular carcinoma cell proliferation via inhibition of the mitogen-activated protein kinases and AKT pathways.
Matsushima-Nishiwaki R; Adachi S; Yoshioka T; Yasuda E; Yamagishi Y; Matsuura J; Muko M; Iwamura R; Noda T; Toyoda H; Kaneoka Y; Okano Y; Kumada T; Kozawa O
J Cell Biochem; 2011 Nov; 112(11):3430-9. PubMed ID: 21769911
[TBL] [Abstract][Full Text] [Related]
8. MUC15 inhibits dimerization of EGFR and PI3K-AKT signaling and is associated with aggressive hepatocellular carcinomas in patients.
Wang RY; Chen L; Chen HY; Hu L; Li L; Sun HY; Jiang F; Zhao J; Liu GM; Tang J; Chen CY; Yang YC; Chang YX; Liu H; Zhang J; Yang Y; Huang G; Shen F; Wu MC; Zhou WP; Wang HY
Gastroenterology; 2013 Dec; 145(6):1436-48.e1-12. PubMed ID: 23933603
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
10. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
[TBL] [Abstract][Full Text] [Related]
11. Anticancer drugs induce hypomethylation of the acetylcholinesterase promoter via a phosphorylated-p38-DNMT1-AChE pathway in apoptotic hepatocellular carcinoma cells.
Xi Q; Gao N; Yang Y; Ye W; Zhang B; Wu J; Jiang G; Zhang X
Int J Biochem Cell Biol; 2015 Nov; 68():21-32. PubMed ID: 26299326
[TBL] [Abstract][Full Text] [Related]
12. Possible role of visfatin in hepatoma progression and the effects of branched-chain amino acids on visfatin-induced proliferation in human hepatoma cells.
Ninomiya S; Shimizu M; Imai K; Takai K; Shiraki M; Hara T; Tsurumi H; Ishizaki S; Moriwaki H
Cancer Prev Res (Phila); 2011 Dec; 4(12):2092-100. PubMed ID: 21952585
[TBL] [Abstract][Full Text] [Related]
13. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
14. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma.
Shen G; Rong X; Zhao J; Yang X; Li H; Jiang H; Zhou Q; Ji T; Huang S; Zhang J; Jia H
Carcinogenesis; 2014 Dec; 35(12):2748-55. PubMed ID: 25280563
[TBL] [Abstract][Full Text] [Related]
15. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway.
Liao J; Xu T; Zheng JX; Lin JM; Cai QY; Yu DB; Peng J
Int J Mol Med; 2013 Jul; 32(1):79-84. PubMed ID: 23613111
[TBL] [Abstract][Full Text] [Related]
16. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway.
Wang S; Huang X; Li Y; Lao H; Zhang Y; Dong H; Xu W; Li JL; Li M
Hepatology; 2011 Jun; 53(6):1932-42. PubMed ID: 21391225
[TBL] [Abstract][Full Text] [Related]
17. Neuregulin/erythroblastic leukemia viral oncogene homolog 3 autocrine loop contributes to invasion and early recurrence of human hepatoma.
Hsieh SY; He JR; Hsu CY; Chen WJ; Bera R; Lin KY; Shih TC; Yu MC; Lin YJ; Chang CJ; Weng WH; Huang SF
Hepatology; 2011 Feb; 53(2):504-16. PubMed ID: 21246584
[TBL] [Abstract][Full Text] [Related]
18. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
[TBL] [Abstract][Full Text] [Related]
19. Combination of cetuximab and rapamycin enhances the therapeutic efficacy in hepatocellular carcinoma.
Geng J; Li X; Lang X; Qiao C; Hu M; Yang J; Feng J; Lv M
Technol Cancer Res Treat; 2014 Aug; 13(4):377-85. PubMed ID: 24325131
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Manov I; Pollak Y; Broneshter R; Iancu TC
FEBS J; 2011 Sep; 278(18):3494-507. PubMed ID: 21790999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
